Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 Million
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 Million
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Product Overview
Mobilized peripheral blood CD34+ hematopoietic stem and progenitor cells are positively selected using a immunomagnetic CD34 microbead labeling system. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using hemacytometer (trypan blue method). Cells are collected from healthy donors following IRB protocols.
Request More InfoBenefits
- Obtain large quantities of CD34+ from a mobilized donor
- Certificate of analysis (CoA) provided for each lot purchased
- HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
Applications
- CAR-T therapy development
- Stem cell physiology
- iPSC generation
- Autoimmune disease
- Immunology
- Cancer therapy research
Storage and Content
1 x Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood containing ≥ 25 million cells
SDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
Instructions and Technical Sheet- Human CD34+ Cells
-
Blood and Immune Cells
Fueling your next discovery with unmatched cell and donor variety -
CD34+ Cells for Cell and Gene Therapy Process Development
In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development. Please register to read.
